Effect of Barley Supplemented Wheat Bread on Markers of Cardiovascular and Renal Health

Effect of Barley Supplemented Wheat Bread on Markers of Cardiovascular and Renal Health: A Randomized Controlled Trial

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05312788

Enrollment

Registered

2022-04-06

Start date

2022-05-04

Completion date

2022-08-10

Last updated

2024-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Diseases, Kidney Diseases

Keywords

TBARs, TAC, pCS, Barley, Beta-glucan, E-selectin, NO

Brief summary

The disruption of colonic microbiota has been linked to a number of diseases, mainly cardiovascular and kidney diseases. One possible means to improve the microbiota is to increase dietary fiber intake as the intake of dietary fiber shifts the fermentation from proteolytic saccharolytic fermentation. Beta-glucans are soluble dietary fibers mainly found in oats and barley. Results from previous studies suggest that the consumption of barley reduces the risk of cardiovascular and kidney diseases. Therefore, this study will explore the effect of barley beta-glucans on markers of Cardiovascular and Renal health.

Interventions

OTHEREffect of Barley Supplemented Wheat Bread on markers of Cardiovascular and Renal Health

Intervention will involve intake of 50% barley substituted wheat bread.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* Healthy individuals of age 18 years or older * BMI ranged between 18.5 and 24.9

Exclusion criteria

* Celiac disease, Cancer, Diabetes , cardiovascular diseases * Gastro intestinal tract disease * Pregnant women * Use of pre-, pro- or antibiotics 15 days before the enrollment into the study * Food allergy to food used in the trial

Design outcomes

Primary

Measure	Time frame
Change in Serum Thiobarbituric acid reactive substances (TBARs) from baseline to 4 weeks	Baseline and after 4 weeks
Change in Serum Total antioxidant capacity (TAC) from baseline to 4 weeks	Baseline and after 4 weeks
Change in Serum Nitric oxide from baseline to 4 weeks	Baseline and after 4 weeks
change in Serum E-selectin from baseline to 4 weeks	Baseline and after 4 weeks
Change in Serum P-cresyl sulfate from baseline to 4 weeks	Baseline and after 4 weeks
Change in Serum Indoxyl sulfate from baseline to 4 weeks	Baseline and after 4 weeks

Countries

Pakistan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026